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Background: Several authorities have proposed stenting of the superior mesenteric artery (SMA)/celiac artery (CA) as the
primary treatment for patients with chronic mesenteric ischemia. However, most of these reports had small samples and
short follow-up periods.
Methods: Eighty-three patients were treated over a 10-year period. Clinical follow-up and duplex ultrasound exams were
done to evaluate long-term patency. We used our newly validated duplex criteria to detect $70% in-stent stenosis of the
SMA and CA. A Kaplan-Meier life-table analysis was used to estimate freedom from in-stent stenosis and late symptom
and survival rates.
Results: Fifty-four SMA and 51 CA stents were analyzed. The initial technical and clinical success rates were 97% and 96%,
respectively,with2%proceduremorbidity and2%mortality.Theprimary late clinical success ratewas59%, and the late$70%
in-stent stenosis ratewas 51%at amean follow-upof 31months (range, 1-124). Freedom from late recurrent symptoms at 1,
2, 3, 4, and 5 years was 83, 77, 70, 70, and 65%, respectively. Survival rates at the same intervals were 88%, 82%, 70%, 64%,
and 51%. Primary patency rates for thewhole series were 69%, 48%, 39%, 28%, and 19% at 1, 2, 3, 4, and 5 years, respectively.
Assisted primary patency rates for the whole series were 80%, 61%, 54%, 43%, and 34% at 1, 2, 3, 4, and 5 years, respectively.
Primary patency rates for the SMA at 1, 2, 3, 4, and 5 years were 71%, 47%, 37%, 28%, and 18%, respectively; and assisted
primary rates were 82%, 64%, 57%, 45%, and 32%, respectively. Primary patency rates for the CAwere 68%, 50%, 40%, 29%,
and21%; and assisted primary rateswere 79%, 58%, 52%, 42%, and 36% for 1, 2, 3, 4, and5 years, respectively. Therewere no
signiﬁcant differences in either primary or assisted primary patency between the SMA and CA (P[ .7729 and .8169). A
secondary interventionwas carriedout in 30%of the series. Freedomfrom$70% in-stent stenosis for theSMAwas82%, 65%,
56%, 42%, and 34%, and that for the CA was 73%, 59%, 48%, 34%, and 25%, at 1, 2, 3, 4, and 5 years, respectively.
Conclusions: Stenting of SMA/CA stenosis has high technical/early clinical success rates with a satisfactory late clinical
outcome; however, it is associatedwith high rates of late in-stent stenosis and intervention. (J Vasc Surg 2013;57:1052-61.)Chronic mesenteric ischemia is thought to occur when
at least two of the three visceral vessels are affected by
severe stenosis or occlusion.1,2 Clinical manifestations are
uncommon owing to the extensive collateral development
of the mesenteric arteries; however, if intestinal blood ﬂow
is unable to supply physiological gastrointestinal demands,
mesenteric ischemia will occur.
Treatment of symptomatic chronic mesenteric ischemia
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2may cause bowel infarction and death. Surgical reconstruc-
tion involves endarterectomy or aortomesenteric and/or
celiac bypass grafting; however, the perioperative mortality
(0%-17%) and morbidity (15%-33%) associated with
surgical intervention are relatively high.2-4 Because of
this, several authors have proposed percutaneous balloon
angioplasty/stenting as the primary treatment in patients
with chronic mesenteric ischemia.4-8
The ﬁrst successful percutaneous angioplasty of the
superior mesenteric artery (SMA) was reported in 1980.9
Since then, several groups have described the results of
percutaneous balloon angioplasty/stenting in the treatment
of chronic mesenteric ischemia, with periprocedural
mortality rates ranging from 0% to 13% and complication
rates from0% to 25%.2-8,10,11However,most series included
small numbers of patients and lacked objective assessment
of treatment durability. The purpose of this study was to
analyze the early perioperative and late clinical outcome of
stenting of the SMA and celiac trunk at our institution.
Our current study is one of the four largest series to
date12-14 of chronic mesenteric ischemia treated with endo-
vascular therapy with a mean follow-up $30 months. It is
Fig 1. Freedom from late clinical symptoms. Cum, Cumulative; SE, standard error.
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artery (CA) using newly validated duplex criteria to
detect$70% in-stent stenosis of the SMA and CA.
METHODS
This is a retrospective analysis of the medical records of
patients with symptoms of chronic mesenteric ischemia
treated with stenting of the CA and SMA over a 10-year
period (June 2000 to June 2010). The institutional review
board of the Charleston Area Medical Center/West Vir-
ginia University, Charleston, West Virginia, approved the
study. These patients were identiﬁed from the vascular
intervention database of the Circulatory Dynamic Labora-
tory. Patients with acute mesenteric ischemia were
excluded. All patients and/or their primary physicians
were contacted by telephone, and every effort was made
for these patients to return for a clinical examination and
follow-up color duplex ultrasound of the SMA/CA. They
had a comprehensive gastrointestinal workup at their initial
presentation and were seen by a gastroenterologist to rule
out other causes of their gastrointestinal symptoms. Preop-
erative evaluation of the mesenteric vessels included duplex
ultrasound of the SMA, celiac trunk, and inferior mesen-
teric artery.
All patients underwent preoperative conventional arteri-
ography to determine the severity of stenosis, which was felt
to be atherosclerotic in origin except for one case of celiactrunk stenosis that was believed to be of uncertain etiology
in a patient who refused initially to have an open procedure.
SMA/CA stenting technique. In summary, 5F cath-
eter sheath delivery systems were advanced through the
abdominal aorta proximal to the level of the mesenteric
vessels, and both anteroposterior and lateral aortography
was performed. Angled selective catheters (eg, SOS Omni)
were used to engage the mesenteric oriﬁce, and selective
angiography was performed. Translesional pressure gradient
measurements were performed in some of the patients in
whom the severity of the stenosis was questioned, and
a 20 mm Hg systolic pressure gradient with a 4F catheter
was considered to be signiﬁcant ($70% stenosis). A variety
of techniques were used to perform the stenting procedure,
based on operator preference. However, the majority of
procedures were performed using a “no-touch” or “tele-
scoping” technique with a guide catheter. With the “no-
touch technique,” a 0.035-inch Supracore wire (Abbott
Vascular, Santa Clara, Calif) is used to prevent the guide
catheter from scraping the aortic wall while a 0.014-inch
wire is advanced into the SMA/CA, whereas in the “tele-
scoping technique,” a diagnostic catheter is advanced
through the guide catheter and the visceral artery is can-
nulated by advancing the 0.014-inch wire into the artery
and advancing the guide catheter over the diagnostic cath-
eter to the ostium to prevent the guide catheter from
scraping the aortic wall.
Fig 2. Primary patency (PP) rates for the whole series. Cum, Cumulative; SE, standard error.
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degree of calciﬁcation, the tortuosity of the vessel, and
whether the lesion was in the oriﬁce or distal to the oriﬁce.
Balloon-expandable stents were used for ostial lesions, and
self-expanding stents were used for lesions distal to the
ostium. Several stents were used in our series including
the Palmaz Genesis and Palmaz Cornithian (Cordis Endo-
vascular, Miami Lakes, Fla) and the Herculink (Guidant,
Santa Clara, Calif). The size and length of the stent were
determined angiographically by measuring the length of
the stenosis to be covered, allowing proximal and distal
extension beyond the lesion and the arterial diameter
immediately distal to the target lesion to be treated. No
attempts were made to treat total artery occlusion. No
embolic protection devices were used in this series. The
stenosis was predilated, if necessary, prior to stenting.
All patients were administered systemic heparin (3000-
5000 units intravenously) prior to stenting and received
300 mg of clopidogrel (Plavix) after the procedure, if not
on Plavix prior to the procedure, followed by 75 mg daily
for 6 to 8 weeks, in addition to 81 to 325 mg of aspirin
daily (depending on operator preference), which was
continued indeﬁnitely.
Deﬁnitions and end points. Technical success was
calculated on a per-vessel basis and was deﬁned as residual
stenosis <30% with a systolic pressure gradient <10 mmHg. Early clinical success was deﬁned as resolution of the
preoperative clinical symptoms of chronic mesenteric
ischemia during the 30-day perioperative period. Late
clinical success rates (no recurrence of symptoms of chronic
mesenteric ischemia) were calculated at the last follow-up
visit for each patient. Primary patency of the mesenteric
arteries (CA or SMA) was based on the duplex ultrasound
examination and/or angiography.
Failed primary patency was used when patients devel-
oped in-stent stenosis/occlusion, whereas assisted primary
patency was determined by follow-up of patients who
underwent repeat endovascular therapy with a failure of
primary patency.15 Although there was no uniform
follow-up protocol in this series, every effort was made to
encourage these patients to be seen 1 month postopera-
tively and every 6 to 12 months after that, depending on
their symptoms. We used our newly validated duplex
velocity criteria to detect $70% in-stent stenosis of the
SMA and the CA.16 Prior to this report, patients with
PSVs >275 cm/s for the SMA and >200 cm/s for the
CA, poststenting, underwent angiography to determine
the need for reintervention, particularly if symptomatic.
Statistical analysis. Kaplan-Meier life-table analyses
were used to estimate survival rates, primary and assisted
primary patency rates, freedom from recurrent $70%
stenosis, and recurrent symptoms. Statistical comparisons
Fig 3. Assisted primary patency (APP) rates for the whole series. Cum, Cumulative; SE, standard error.
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success rates were calculated at the last follow-up visit on
a per-patient basis.
RESULTS
Eighty-three patients underwent 105 stentings of the
CA or SMA during this period. There were 51 SMA stent-
ings and 54 CA stentings (22 had both SMA and CA stent-
ing). Nineteen patients had open bypass to SMA/CA
during the same period with a perioperative mortality
rate of 10.5% (2/19). The mean age of these patients
who had percutaneous balloon angioplasty/stenting was
70.5 years (range, 45-90), and 84% were women. Their
comorbidities included hypertension in 81%, diabetes mel-
litus in 28%, coronary artery disease in 61%, hypercholester-
olemia in 47%, chronic renal insufﬁciency in 25%, and
smoking in 53%. Ninety-three percent of these patients
presented with postprandial pain (intestinal angina).
A signiﬁcant bulk of these patients also had a weight
loss >10 pounds over 6 months (47%) or gastrointestinal
symptoms (51% had nausea/vomiting and/or diarrhea
and 11% had food fear). The mean follow-up for the group
was 31.3 months (range, 1-124). The initial technical
success rate was 97%; three patients had unsuccessful recan-
alization, two of the CA and one of the SMA. The early
clinical success rate was 96%; four patients had early clinicalfailure, including three patients with technical failure and
one patient with no relief of symptoms. One of the three
technical failures was in a patient with angiographic ﬁnd-
ings atypical for median arcuate ligament syndrome; the
lesion would not yield, and ultimately, the patient under-
went surgical reconstruction for median arcuate ligament
syndrome without incidence. Thirty-day perioperative
major complication and mortality rates were 2% and 2%;
one patient had acute renal failure and a myocardial infarc-
tion and the other patient had thrombosis of the mesen-
teric vessel, which was followed by bowel infarction,
sepsis, multiple system failure, and death.
Late clinical outcome. Thirty of 73 (41%) patients
with long-term follow-up had late recurrent clinical symp-
toms at a mean of 31 months. It should be noted that
10 patients had no follow-up beyond 1 month. Forty-three
of 84 (51%) arteries, with $1 month duplex/angiogram
follow-up, had late$70% in-stent stenosis: 11 of these were
asymptomatic. Overall, there were 45 arteries with$70% in-
stent stenosis, but two had a follow-up <1 month. Twenty-
ﬁve (all symptomatic) of 84 arteries (30%) required
a secondary intervention, including 13 that underwent
repeat percutaneous balloon angioplasty, eight that required
restenting, three that had percutaneous balloon angioplasty
and restenting, and one that required aortic-to-SMA/CA
bypass grafting (had total occlusion of both the SMA and
Fig 4. Primary patency (PP) rates for the superior mesenteric artery (SMA) and celiac artery (CA) separately. Cum,
Cumulative; SE, standard error.
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stenosis (four had $50% in-stent stenosis). The remaining
22 patients with late $70% in-stent stenosis had no sec-
ondary intervention: 11 were asymptomatic and 11 refused
further intervention or were too sick to undergo further
intervention. Among the 25 reinterventions, the mean time
to reintervention was 33.5 months (range, 1-124). Fig 1
illustrates freedom from late clinical symptoms. As noted,
the rates of freedom from late symptoms were 83%, 77%,
70%, 70%, and 65% at 1, 2, 3, 4, and 5 years, respectively.
There was no statistically signiﬁcant difference in clinical
outcome between patients with only CA or only SMA
stenting and those with stenting of both CA and SMA.
SMA/CA patency. Figs 2 and 3 illustrate primary
patency and assisted primary patency for the whole series.
Primary patency for thewhole series was 69%, 48%, 39%, 28%,
and 19% at 1, 2, 3, 4, and 5 years, respectively (Fig 2). Assisted
primary patency for the whole series was 80%, 61%, 54%, 43%,
and 34% at 1, 2, 3, 4, and 5 years, respectively (Fig 3).
Figs 4 and 5 illustrate primary and assisted primary
patency for the SMA and CA separately. Primary patency
of the SMA at 1, 2, 3, 4, and 5 years was 71%, 47%,
37%, 28%, and 18%, respectively; and assisted primary
patency was 82%, 64%, 57%, 45%, and 32%, respectively.
Primary patency of the CA was 68%, 50%, 40%, 29%, and21%, and assisted primary patency was 79%, 58%, 52%,
42%, and 36%, at 1, 2, 3, 4, and 5 years, respectively. There
were no signiﬁcant differences in either primary or assisted
primary patency between the SMA and CA groups (P ¼
.7729 and .8169).
Freedom from $70% in-stent stenosis, illustrated in
Fig 6, was 82%, 65%, 56%, 42%, and 34% for the SMA
and 73%, 59%, 48%, 34%, and 25% for the CA, at 1, 2, 3,
4, and 5 years, respectively (Fig 6). Again, there were no
signiﬁcant differences between the SMA and CA groups
(P ¼ .5759).
Survival rates at 1, 2, 3, 4, and 5 years were 88%, 82%,
70%, 64%, and 51%, respectively (Fig 7). Reintervention-
free survival rates at 1, 2, 3, 4, and 5 years were 79%, 70%,
49%, 41%, and 38%. Overall, 25 patients died, two perioper-
atively and 23 late; ﬁve died from cardiac causes, one from
stroke, three from sepsis, two from pulmonary causes, one
from bowel gangrene, three from cancer, and the remainder
from unknown causes.
DISCUSSION
There are a paucity of studies evaluating the natural
history of asymptomatic SMA/CA stenosis. However, it
appears that development of chronic or acute mesenteric
ischemia is uncommon unless the SMA, CA, and inferior
Fig 5. Assisted primary patency (APP) rates for the superior mesenteric artery (SMA) and celiac artery (CA) separately.
Cum, Cumulative; SE, standard error.
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known that the natural history of a patient with symptomatic
chronic mesenteric ischemia is not favorable and carries
signiﬁcant morbidity and the risk of mortality from acute
mesenteric ischemia19 and that revascularization is indicated
for these patients. The ﬁrst open surgical revascularization
for mesenteric ischemia was surgical thromboendarterec-
tomy of the SMA, which was reported in 1958.20 Although
bypass has now become the more common open surgical
procedure used for mesenteric revascularization in patients
with chronic mesenteric ischemia, open surgical revasculari-
zation (OSR) has become proportionally much less
commonly used than endovascular revascularization
(ER).21 In fact, by 2005, SMA/CA angioplasty and stenting
had surpassed the number of open surgical procedures.21
There are studies that have compared the results of
OSR and ER with respect to chronic mesenteric ischemia.
Kasirajan et al3 compared 28 patients who underwent ER
with 85 patients who underwent OSR. The study demon-
strated no signiﬁcant difference in early in-hospital compli-
cations (median, 17.9% for ER and 32.9% for OSR;
P ¼ .12) or mortality rate (median, 10.7% for ER and
8.2% for OSR; P ¼ .71). Average hospital stay trended
toward being decreased in the ER group but did not statis-
tically differ (median, 5 days for ER and 13 days for OSR;P ¼ .08). There was no difference in recurrent stenosis at 3
years in the two groups; however, there was a signiﬁcant
difference in the recurrence of symptoms (median, 34%
for ER and 13% for OSR; P ¼ .001). There are limitations
to the study by Kasirajan et al3 including the use of balloon
angioplasty alone in ﬁve patients and the small number of
ER procedures performed compared with OSR proce-
dures. Postoperative mortality was quite high for the ER
group, with three of 28 patients dying, two from bowel
gangrene. This is much higher than the 2% 30-day
mortality rate in our series. This difference may be related
to improving technology.
A second study by Oderich et al22 compared OSR and
ER for patients with chronic mesenteric ischemia. OSR was
performed on 146 patients and ER was performed on 83
patients.Therewas nodifference in procedure-relateddeaths
(2.7% for OSR; 2.4% for ER; P ¼ not signiﬁcant); however,
there were more complications in the OSR group than in
the ER group (36% for OSR; 18% for ER; P < .001). There
was also a statistically increased length of hospital stay in the
OSR group (12 6 8 days in OSR; 3 6 5 days in ER; P <
.001). As expected, primary patency rates were improved at
5 years in the OSR group (88 6 3% in OSR; 41 6 9% in
ER), although secondary patency rates were greatly
improved in the ER group (97 6 2% for OSR; 88 6 4% for
Fig 6. Freedom from $70% in-stent stenosis for the superior mesenteric artery (SMA) and celiac artery (CA). Cum,
Cumulative; SE, standard error.
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ences in symptom improvement between the two groups
(96% for OSR; 92% for ER; P ¼ not signiﬁcant). The study
by Oderich et al22 had a perioperative mortality rate in ER
patients similar to that in our study (2.4% vs 2%) but also
had excellent procedure-related mortality for OSR at 2.7%
and performed a larger number of ER procedures when
compared with the study by Kasirajan et al.3
Finally, a third study by Atkins et al1 also compared
OSR and ER in patients with chronic mesenteric ischemia.
In that study, 31 patients underwent ER and 49 patients
underwent OSR for treatment of chronic mesenteric
ischemia. As expected, hospital stay was less for patients
who had ER than for those who underwent OSR (5.6
days for ER; 16.7 days for OSR). In Atkins et al’s study,
however, there was no difference in major morbidity
(13% for ER; 4% for OSR; P ¼ .14) or in-hospital mortality
(3% for ER; 2% for OSR; P ¼ .74) between the two
groups. Primary patency was higher in the OSR group
(58% for ER; 90% for OSR; P ¼ .001), as was assisted
primary patency (65% for ER; 96% for OSR; P < .001)
at 1 year. Importantly, there was no difference in the inci-
dence of symptom recurrence (23% for ER; 22% for OSR;
P ¼ .98).
In evaluation of these three studies together, it is
important to realize that they were all performed at centersof excellence (Mayo Clinic, Cleveland Clinic, and Massa-
chusetts General Hospital) and had excellent overall perio-
perative mortality rates for OSR in patients with chronic
mesenteric ischemia (range, 2%-8.2%), lower than the
national average mortality rate. The national in-hospital
mortality rate for OSR from 1988 to 2006 on 16,071
procedures was 13% compared with 3.7% for 6342 ER
procedures (P < .01) for patients with chronic mesenteric
ischemia.21 When procedures completed from 2000 to
2006 were separated and evaluated, in-hospital mortality
was 3.7% for ER and 15% for OSR (P < .001). This is
a more “real-world” evaluation of outcome, and the
mortality rate of 3.7% for ER was also higher than the
mortality rate of 2% in our cohort.
Indes et al23 reported on the outcomes of endovascular
and open treatment for chronic mesenteric ischemia using
a New York State Health Department database for chronic
mesenteric ischemia for 2000 to 2006. During that time,
6549 patients were evaluated for chronic mesenteric
ischemia in New York State. Of these patients, 666 received
an intervention and underwent either open (n ¼ 280) or
endovascular (n ¼ 347) repair. Over the 7-year study
period, there was a steady increase in the proportion of
endovascular procedures, from 28% in 2000 to 75% in
2006. The overall mortality rate was signiﬁcantly lower for
endovascular vs open repair (11.0% vs 20.4%, respectively;
Fig 7. Survival rates. Cum Surv, Cumulative survival; SE, standard error.
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icantly lower rate of mesenteric ischemic complications
compared with open repair (6.92% vs 17.1%, respectively;
P < .0001). Moreover, compared with open surgery, endo-
vascular repair resulted in signiﬁcantly lower rates of cardiac,
pulmonary, and infectious complications (P < .05). Only
37% of patients who had open repair were discharged
home compared with 55% of patients treated with endovas-
cular procedures (P < .0001).23
In most centers across the country, the preferred ﬁrst-
line treatment for chronic mesenteric ischemia is ER because
of the increased mortality risk associated with OSR, and this
has now been our treatment strategy for several years.
Numerous retrospective studies have evaluated the
outcome of ER for chronic mesenteric ischemia. Some of
these studies included patients in which angioplasty alone
and primary stenting were both included,1,3,22,24-27
whereas other studies evaluated patients who underwent
only stenting.12,13,28-32 Routine primary stenting, rather
than angioplasty alone, has become the standard of care
in most institutions for the treatment of SMA and CA
occlusive disease. There is a lack of evidence-based medi-
cine to support the use of primary stenting33; however,
given the frequent heavy calcium burden associated withSMA and CA aorto-ostial lesions, the use of balloon
expandable stents to prevent elastic recoil after intervention
is intuitive. The Table lists studies with long-term follow-up
that include at least 25 patients and in which stenting was
used in all patients.12,13,28-30 A total of ﬁve previous studies
were found that matched these criteria. As noted in these
studies, the perioperative mortality rate was found to range
from 0% to 7.7%, and the complication rate, from 2% to
30.8%. Interestingly, if Sarac and colleagues study, which
includes patients with total occlusions (18%, 65 patients)
and had the highest perioperative mortality (7.7%) and
complication rates (30.8%), is excluded, then perioperative
mortality (0%-4%) and complication (2%-23%) rates are
signiﬁcantly improved.
Long-term clinical outcomes (symptom relief) appear
to be reasonable with ER for chronic mesenteric ischemia.
In our cohort, long-term symptom relief was 65% at 5
years. The other studies listed in the Table varied in length
of follow-up, but all studies reported reasonable symptom
relief on follow-up. However, the durability of ER (stent
patency) for chronic mesenteric ischemia is not equal to
that of stenting in other locations such as the iliac artery,
for which 5-year patency is 82% and 10-year patency is
75%.34 In our cohort, 1-year primary patency was 69%;
Table. Review of previous studies evaluating endovascular therapy for chronic mesenteric ischemia
Author, year
No. of
patients
No. of
vessels
Perioperative
mortality
rate
Complication
rate
Long-term
symptom
relief
1-year
primary
patency
1-year
primary-assisted
patency
Mean
follow-up,
months
Sharafuddin et al,28 2003 25 26 4% 10% 92% (mean follow-up) NA NA 15
Silva et al,13 2006 59 79 1.7% 5% 83% (mean follow-up) NA NA 38
Sarac et al,12 2008 65 87 7.7% 30.8% 75% (1 year) 65% 97% 12
Fioole et al,29 2010 51 60 0% 4% 68% (2 years) 86% 88% 25
Dias et al,30 2010 43 49 0% 23% 88% (3 years) NA NA 43
AbuRahma et al,16 2012 83 105 2% 2% 65% (5 years) 68% 79% 31
NA, Not assessed.
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80%. Unfortunately, long-term durability was much lower,
with a primary patency of 19% and an assisted primary
patency of 34% at 5 years. It must, however, be noted
that only nine arteries were at risk at 5 years because of
poor survival and loss to follow-up, and this may have
adversely impacted the results. This small number at
a late interval also decreases the standard error of the
outcome estimates. We believe that close duplex surveil-
lance is essential given that performing an intervention on
a stent with restenosis is less perilous than performing an
intervention on a stent that is occluded.
After a systematic literature search of the Medline data-
base between 1988 and 2009, van Petersen et al35 concluded
that endovascular therapy of the mesenteric vessels has the
advantage of low short-term morbidity, but the disadvantage
of decreased long-term primary patency, compared with
open revascularization. Endovascular therapy and open re-
vascularization have similar rates of secondary patency, but
endovascular therapy has a higher rate of reintervention.
Lastly, our cohort did have a very poor 5-year survival
rate, as only 51% of the patients survived to 5 years. This is
not surprising. In a study by Rawat et al,36 5-year survival
was 63% in patients who had OSR and 31% in patients
who had ER. In that study, the patients who had ER were
signiﬁcantly older and tended to have greater comorbidities;
however, both groups had signiﬁcant 5-year mortality. This is
not surprising, and high long-term mortality is observed in
patients undergoing endovascular interventions in other arte-
rial beds such as the renal artery (66.6% at 5 years).37
There are some limitations to our study. The most
important is that the study was retrospective. Data collec-
tion was dependent on chart review, and the decision to
treat a solitary artery or both the mesenteric and celiac
arteries was based on operator preference. Another limita-
tion is that given the long study period, there was hetero-
geneity in the procedural techniques used for mesenteric
stenting. It should also be noted that this series excluded
patients with total occlusion.
CONCLUSIONS
This study shows that stenting of the superior mesen-
teric and celiac arteries can be highly technically and
clinically successful. The perioperative complication and
mortality rates are low, and the procedure can beperformed safely in most patients. However, although the
freedom from recurrent symptoms is acceptable, primary
patency rates are low and many patients do require
reintervention.
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